These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 16447119

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 3. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts.
    Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Séréni D, Viard JP, Delfraissy JF, Meyer L, SEROCO Cohort Study Group.
    J Infect Dis; 2005 Jul 01; 192(1):46-55. PubMed ID: 15942893
    [Abstract] [Full Text] [Related]

  • 4. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM, AIDS Clinical Trials Group 5170 Study Team.
    J Infect Dis; 2007 May 15; 195(10):1426-36. PubMed ID: 17436222
    [Abstract] [Full Text] [Related]

  • 5. Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort.
    Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, Zitoun Y, Allègre T, Delfraissy JF, Meyer L, Rouzioux C, ANRS PRIMO Cohort.
    J Antimicrob Chemother; 2010 Apr 15; 65(4):741-8. PubMed ID: 20167586
    [Abstract] [Full Text] [Related]

  • 6. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
    Piketty C, Weiss L, Assoumou L, Burgard M, Mélard A, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D, ANRS 116 SALTO Study Group.
    J Med Virol; 2010 Nov 15; 82(11):1819-28. PubMed ID: 20872707
    [Abstract] [Full Text] [Related]

  • 7. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G, Italian MASTER Cohort.
    Antivir Ther; 2007 Nov 15; 12(6):941-7. PubMed ID: 17926648
    [Abstract] [Full Text] [Related]

  • 8. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ, Till M, Palella FJ, Knoll MD, Terp SM, Kalnins AU, Murphy RL.
    HIV Med; 2005 Jan 15; 6(1):7-12. PubMed ID: 15670246
    [Abstract] [Full Text] [Related]

  • 9. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 10. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 11. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD.
    N Engl J Med; 1996 Feb 15; 334(7):426-31. PubMed ID: 8552144
    [Abstract] [Full Text] [Related]

  • 12. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation.
    Martinez V, Diemert MC, Braibant M, Potard V, Charuel JL, Barin F, Costagliola D, Caumes E, Clauvel JP, Autran B, Musset L, ALT ANRS CO15 Study Group.
    Clin Infect Dis; 2009 Jan 01; 48(1):123-32. PubMed ID: 19035778
    [Abstract] [Full Text] [Related]

  • 13. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C, Gourlain K, Tubiana R, Carcelain G, Marcelin AG, Chouquet C, Mouroux M, Duvivier C, Autran B, Costagliola D, Katlama C, Calvez V.
    Antivir Ther; 2003 Jun 01; 8(3):233-7. PubMed ID: 12924540
    [Abstract] [Full Text] [Related]

  • 14. Heat-denatured human immunodeficiency virus type 1 protein 24 antigen: prognostic value in adults with early-stage disease.
    Sterling TR, Hoover DR, Astemborski J, Vlahov D, Bartlett JG, Schupbach J.
    J Infect Dis; 2002 Oct 15; 186(8):1181-5. PubMed ID: 12355373
    [Abstract] [Full Text] [Related]

  • 15. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R.
    J Infect Dis; 2006 Jul 01; 194(1):29-37. PubMed ID: 16741879
    [Abstract] [Full Text] [Related]

  • 16. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, Swiss HIV Cohort Study.
    Clin Infect Dis; 2008 Oct 15; 47(8):1093-101. PubMed ID: 18783328
    [Abstract] [Full Text] [Related]

  • 17. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA, Ferreccio C, Abarca K, Ortiz E, Noriega M, Pérez C, Labarca J, Torres M, Ferrés M, González C, Acuña G.
    Rev Med Chil; 1996 May 15; 124(5):525-35. PubMed ID: 9035503
    [Abstract] [Full Text] [Related]

  • 18. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
    Gandhi T, Wei W, Amin K, Kazanjian P.
    Clin Infect Dis; 2006 Mar 15; 42(6):878-84. PubMed ID: 16477568
    [Abstract] [Full Text] [Related]

  • 19. CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/l.
    Mussini C, Bedini A, Borghi V, Guaraldi G, Esposito R, Barchi E, Enilia R, Cozzi-Lepri A, Philips AN, Ortolani P, Bratt G, Eriksson LE, Sighinolfi L, Cossarizza A, d'Arminio Monforte A, De Luca A, Di Giambenedetto S, Antinori A, International Study Group on CD4-monitored Treatment Interruptions.
    AIDS; 2005 Feb 18; 19(3):287-94. PubMed ID: 15718839
    [Abstract] [Full Text] [Related]

  • 20. [Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].
    Romeu J, Balagué M, Ruiz L, Marfil S, Puig T, Arnó A, Veny A, Tural C, Sirera G, Clotet B.
    Med Clin (Barc); 1998 Jun 06; 110(20):761-7. PubMed ID: 9666416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.